Europe: time between combination therapies authorization and access 2024, by country| Statista

This statistic displays the average time between a combination therapy gaining marketing authorization and patient access in European countries as of January 1, 2024. According to the data, Switzerland had an average time of 201 days between authorization and patient access for combination therapies (for therapies launched from 2018 to 2021), compared to around 760 days in Poland.

Average time between marketing authorization and patient access for combination therapies in Europe as of 2024, by country (in days)

Characteristic	Average time in days
North Macedonia*	99
Denmark	133
Germany	159
Switzerland	201
England***	255
Scotland***	258
Bosnia and Herzegovina*	262
Serbia	264
Slovenia	271
Estonia	282
Sweden	289
France**	304
Ireland	315

050100150200250300350400450500550600650700750800850

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

June 2024

More information

Region

Europe

Survey time period

as of January 5, 2024

Supplementary notes

Data collected is for drugs launched from 2019 to 2022. In most countries, availability equates to granting of access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme. The time to availability (formerly known as length of delay) is the days between EMA marketing authorization and the date of availability to patients.

* These countries did not complete a full dataset and therefore availability may be unrepresentative.
** The source mentions that it does not consider France's system of temporary authorization for some products, which means this time will be higher than in reality.
*** MHRA’s Early Access to Medicines Scheme provides access before marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.

Citation formats